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Background: The development of vectors for cell-specific gene delivery is a major goal of gene therapeutic
strategies. Transferrin receptor (TfR) is an endocytic receptor and identified as tumor relative specific due to its
overexpression on most tumor cells or tissues, and TfR binds and intakes of transferrin-iron complex. We have
previously generated an anti-TfR single-chain variable fragments of immunoglobulin (scFv) which were cloned from
hybridoma cell line producing antibody against TfR linked with a 20 aa-long linker sequence (G4S)4. In the present
study, the anti-TfR single-chain antibody (TfRscFv) was fused to DNA-binding domain of the yeast transcription
factor GAL4. The recombinant fusion protein, designated as TfRscFv-GAL4, is expected to mediate the entry of
DNA-protein complex into targeted tumor cells.
Results: Fusion protein TfRscFv-GAL4 was expressed in an E. coli bacterial expression system and was recovered
from inclusion bodies with subsequent purification by metal-chelate chromatography. The resulting proteins were
predominantly monomeric and, upon refolding, became a soluble biologically active bifunctional protein. In
biological assays, the antigen-binding activity of the re-natured protein, TfRscFv-GAL4, was confirmed by specific
binding to different cancer cells and tumor tissues. The cell binding rates, as indicated by flow cytometry (FCM)
analysis, ranged from 54.11% to 8.23% in seven different human carcinoma cell lines. It showed similar affinity and
binding potency as those of parent full-length mouse anti-TfR antibody. The positive binding rates to tumor tissues
by tissue microarrays (TMA) assays were 75.32% and 63.25%, but it showed weakly binding with hepatic tissue in 5
cases, and normal tissues such as heart, spleen, adrenal cortex blood vessel and stomach. In addition, the
re-natured fusion protein TfRscFv-GAL4 was used in an ELISA with rabbit anti-GAL4 antibody. The GAL4-DNA
functional assay through the GAL4 complementary conjugation with the GAL4rec-GFP-pGes plasmid to verify the
GLA4 activity and GAL4rec-recognized specificity functions. It also shows the complex, TfRscFv-GAL4-GAL4rec-GFP-
pGes, could be taken into endochylema to express the green fluorescent protein (GFP) with 8 to 10-fold
transfection efficiency.
Conclusions: Results of our study demonstrated that the biofunctianality of genetically engineered fusion protein,
TfRscFv-GAL4, was retained, as the fusion protein could both carry the plasmid of GAL4rec-pGes and bind TfR on
tumour cells. This product was able to transfect target cells effectively in an immuno-specific manner, resulting in
transient gene expression. This protein that can be applied as an effective therapeutic and diagnostic delivery to
the tumor using endogenous membrane transport system with potential widespread utility.* Correspondence: zhwang_hust@hotmail.com
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The development of efficient and non-toxic vectors for
cell-specific gene delivery is a major challenge in gene
therapeutic research. A significant progress has been made
in the construction of non-viral vectors that combine dif-
ferent functions required for gene transfer in an artificial
complex, as the potential advantages of such a system in-
clude ease of use, cost-effective large-scale manufacture,
purity, homogeneity, as well as fewer and more well-
defined regulatory issues [1,2]. However, the alterna-
tive approaches relying on the activities of natural or
recombinant DNA-carrier proteins to achieve uptake
and intracellular delivery of plasmid DNA has not
been developed.
Transferrin (Tf) plays an important role in the cellular
iron uptake. Once Tf binds with transferrin receptor
(TfR, CD71) on the cell surface, it is ingested into the
endosome under acidic condition. During this process,
iron is released and the TfR-apo-Tf complexes then re-
circulate into the cell surface. Upon disassociation of
TfR, apo-Tf regains the ability of binding to iron again.
TfR is a cell membrane-associated glycoprotein involved
in the cellular uptake of iron and in the regulation of cell
growth [3] and it is preferentially expressed in cells with
high potential for proliferation. Therefore, the remark-
able and stable TfR expression can be detected in various
tumor cells such as hepatoma carcinoma cells and
leukemia cells [4-7]. Given its abundance in malignant
tissues and its significance in the cellular iron uptake,
TfR could therefore be used as a biomarker for tumor
cells in addition to its relevance in cancer and its extra-
cellular accessibility. These characteristics also render
TfR to be an excellent antigen for antibody-based cancer
therapy [8]. Indeed, many TfR-specific antibodies (mAbs)
have been developed and employed to kill the malignant
cells in vitro and in vivo [9-11]. Previously, we have suc-
cessfully developed several antibodies against TfR includ-
ing the human-mouse chimeric antibody, intracellular
antibody and bivalent single chain variable fragment
(bsFv) antibody [6,12-14]. All of these antibodies displayed
tumor-specific biodistribution with substantial antitumor
activity. We also employed a transferrin-polyethylenimine
(Tf–PEI) delivery system to carry HIF-1α shRNAs in-
to distant tumors. Our studies demonstrated that TfR-
mediated endocytosis could induce HIF-1α silencing and
resulted in impaired xenograft growth of melanoma
in vivo [15]. Together, these studies support the possibility
that antibodies specific for TfR could be used as a feasible
carrier of genes to target for tumor therapy or diagnosis.
However, in comparison with the whole antibody or trans-
ferin molecule, the scFv has a smaller size for a better
penetration into tumor cells. Indeed, low molecule weight
single-stranded antibody can be conjugated with various
therapeutic or diagnostic molecules to generate targetingcomplex. Also, the internalized TfR-complex can facilitate
the development of tumor therapy or imaging.
The nuclear protein GAL4 is a positive regulator
for galactose-induced gene expressions such as GAL1,
GAL2, GAL7, GAL10, and MEL1 [16]. The high-affinity
of well-characterized of GAL4 DNA-binding has pre-
viously been shown to be retained when placed in the
context of a heterologous fusion partner or used to
enhance gene delivery through conjugation of ligand
and other cationic polymers [1,2,17]. GAL4 possesses
high binding affinity for a specific 17-bp oligonucleo-
tide sequence (5'-cggrnnrcynyncnccg-3', GAL4rec) and
acts as a nuclear localization signal (NLS) [18]. Most
importantly, its specific DNA-binding domain (DBD)
can bind to the plasmid containing an anti-tumor
gene or a specific target gene for imaging. These proper-
ties make it a good candidate for use as a vehicle for
gene transfer.
In the present study, we developed a particularly ap-
pealing approach for the delivery of genes through the
use of recombinant protein-based vehicles which con-
sists of a DNA-binding motif fused to a cell-binding
TfR-scFv. The TfRscFv-GAL4 protein has a dual func-
tion: specific DNA binding via GAL4-DBD and the
GAL4rec of the DNA plasmid, and intracellular delivery
of the target DNA by TfR-scFv transport. This TfRscFv-
GAL4 fusion-mediated DNA delivery system effectively
transduced the pGFP-plasmid and induced GFP expres-
sion in mammalian cells. We further explored its feasi-
bility for application of tumor-targeted drug delivery and
in vivo imaging.
Results
Construction of TfRscFv-GAL4pET expression vector,
expression, purification and renaturation of TfRscFv-GAL4
fusion protein in E. coli
The plasmid for TfRscFv-GAL4 fusion protein was con-
structed as described. Sequencing analysis of the inserts
matched exactly with the targeted gene sequences in the
database (website: http://www.ncbi.nlm.nh.gov/blast). The
full-length sequence for the TfRscFv-GAL4 coding region
was identical with the NcoI-scFv-EcoRI-GAL4-NotI se-
quence (Figure 1).
High levels TfRscFv-GAL4 of expression of was in-
duced in pET28/TfRscFv-GAL4 transformed BL21 (DE3)
E. coli upon the addition of 1mM IPTG. The optimal in-
duction temperature of 30°C was determined to yield
the maximum level of protein expression as shown in
Lane 2 of Figure 2A. The majority of the fusion protein
(~90%) was found not to be soluble but to be contained
within the inclusion bodies. Therefore, the TfRscFv-
GAL4 containing the His-tagged was purified from the
inclusion bodies as described in “Methods.” As shown in
Figure 2B, The TfRscFv-GAL4 fusion protein was then
Figure 1 Construction strategy of TfRscFv-GAL4 prokaryotic expression vector. The prokaryotic expression vector pET28-a was used as the
backbone, the heavy chain (VH) and the light chain (VL) of ScFv was connected with a linker (VH-linker-VL), the His-tag of GAL4 DNA Binding
Domain(GAL4-DBD) was fused to the 3’-end of the VH-linker-VL sequence to express the tag conjugated to C-terminal of the single-chain
antibody. The whole sequence was cloned into the NcoI-NotI restriction site to get a prokaryotic expression vector of TfRscFv-GAL4-pET. The steps
taken in the construction of each plasmid are detailed in Methods.
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using the Ni–NTA column and re-natured by urea gra-
dient dialysis. SDS-PAGE showed a single band of the
re-folded and purified fusion protein with an approxi-
mate molecular weight of 45 ~66.2 kDa, in agreement
with the expected molecular weight (46.7 kDa) for the
recombinant fusion protein, as well as the highest ex-
pression were noted 6h after IPTG induction at 30°C. In
contrast, no reactive band was detected in BL21 E. coli
transformed with an empty vector (Figure 2B). TheFigure 2 Expression and purification of TfRscFv-GAL4 fusion protein.
bodies after IPTG induction at different temperature. BL21 E.coli cell were tr
showed that Inclusion bodies extract after IPTG induced 24 hours at 37°C (
marker. B, after IPTG induced 24 hours at 30°C at different time, Western b
bodies by IMAC, as showed in 0h (lane 1), 4h (lane 2), 6h (lane 3), and BL21
(lane 4). The highest level of protein expression was at 6h after induction.concentration of re-natured protein was 1.7 mg/ml as
measured by the BCA Protein Assay.
Immunoreactivity of TfRscFv-GAL4 with various tumor cell
lines
The binding of TfRscFv-GAL4 to the TfR was studied by
flow cytometry using the TfR overexpression on tumor
cell lines. We next sought to determine the antigen-
binding activity for the TfRscFv-GAL4 fusion protein
with various tumor cells. Flow cytometry analysis wasA, SDS-PAGE showing the fusion protein levels present in the inclusion
ansformed with TfRscFv-GAL4-pET plasmid and gene expression was
Lane1), 30°C (Lane2), 23°C (Lane3). Lane M: protein molecular weight
lotting analysis TfRscFv-GAL4 fusion protein purified from inclusion
E.coli transformed with an empty vector
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TfRscFv-GAL4 group (Figure 3A, TfRscFv-GAL4 group)
and the positive controls (Figure 3A, Mouse anti-TfR
group) showed positive results by flow cytometry assay,
while the negative controls failed to detect any positive
cells (Figure 3A, Mouse IgG group and GAL4 group).
As shown in Figure 3B, the binding rate for TfRscFv-
GAL4 fusion protein with 7 different tumor cells varied
between 8.23% to 54.11%, and there was a significant dif-
ference in terms of the binding rate between the
TfRscFv-GAL4 group and the negative control group
(p<0.01). It showed that the purified TfRscFv-GAL4Figure 3 Flow cytometry demonstrated the immunoreactivity of the T
cells. The cells were incubated with either negative control mouse non-sp
TfRscFv-GAL4 fusion protein or mouse anti-GAL4 antibody used for detecti
The proportion of FITC positive cell to the whole cell was calculated as sho
difference in the binding rate between the TfRscFv-GAL4 group and the ne
representatives of four studies that have been done.retained its immunoreactivity comparable with that of
the parental anti-TfR mAb.
Ag-binding potency of TfRscFv-GAL4 with various tissue
microarray (TMA) sections
According to the standard of TMA sections described in
“Methods”, for gastric cancer TMA sections (total 140
cases), the available cases was 115 for TfRscFv-GAL4 fu-
sion protein group, 95 for mouse anti-TfR antibody
group, were 116 and 113 in mouse anti-GAL4 antibody
group and mouse nonspecific IgG group, respectively.
The available ratios were 85%, 70%, 85% and 83%,fRscFv-GAL4 to TfR expressed on the surface of different tumor
ecific IgG, positive control Mouse anti-TfR monoclonal antibody,
on of GAL4 domain, followed by FITC-labeled goat anti- mouse IgG.
wed in A, The statistical results presents there was significantly
gative control groups as showed in B (p<0.01), these results are
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tive ratios were 75.32%, 78.46%, 0% and 0%, respectively
(Figure 4A,C,E and G). For two breast cancer TMA sec-
tions (total 112 cases), the available cases were 110, 108,
109 and 108, respectively; the available ratios were 98%,
96%, 97% and 96%, respectively. For two breast cancer
TMA sections, the positive ratios were 63.25%, 64.57%,
0% and 0%, respectively (Figure 4B,D,F, and H). The
available ratios and positive ratios for TMA sec-Figure 4 Binding activity of TfRscFv-GAL4 fusion protein to gastric ca
breast cancer tissue were embeded into TMA, dissect into 5μm and placed
chain antibodies were used to bind to the TMA sections (SP: × 400) A-B. M
HRP conjugated goat anti-mouse antibody and DAB were used for detectio
used as positive control (SP: × 400) C-D. The typical immunohistology resu
A-D (SP: × 400). Both anti-GLA4 antibody and normal mouse IgG were use
binding activity with tumor tissues (SP: × 400) E-H. Table 1 showed the stations were showed in Table 1. There was a significant
difference for the positive ratio between the TfRscFv-
GAL4 group and the negative control group (mouse anti-
GAL4 group and mouse nonspecific IgG group) (p<0.01).
In contrast to the normal tissue sections, only 5 liver
cases for the normal tissue sections showed weakly posi-
tive for the TfRscFv-GAL4 fusion protein group and
mouse anti-TfR antibody group, while other tissues in-
cluding the heart, spleen, adrenal cortex, blood vesselsncer and breast cancer in TMA. 140 gastric cancer tissue and 112
on one slide to make tissue microarray sections, TfRscFv-GAL4 single-
ouse anti-GAL4 antibody was used to bind the single-chain antibody,
n of TfR protein expression. Parental mouse anti-TfR antibody was
lts of positive binding activity with tumor tissues have been shown in
d as negative control were typical immunohistology results of negative
tistic data of all tissue in immunohistology results.
Table 1 The staining results and positive rate of the different tumor of TMA
Gastric cancer tissue microarray sections (n=140) Breast cancer tissue microarray sections (n=112)
Available cases Available ratio (%) Positive ratio (%) Available cases Available ratio (%) Positive ratio (%)
TfRscFv-GAL4 115 85 75.32 110 98 63.25
anti-TfR mAb 95 70 78.46 108 96 64.57
anti-GAL4 mAb 116 85 0 109 97 0
nonspecific IgG 113 83 0 108 96 0
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Of note, all normal tissue sections were negative for
the mouse anti-GAL4 group and mouse nonspecific
IgG group.
Reactivity of TfRscFv-GAL4 with anti-GAL4 antibody
To measure the binding activity of GAL4 domain for the
purified TfRscFv-GAL4 fusion protein, we performed
the ELISA analysis. The results revealed that both
TfRscFv-GAL4 fusion protein and GAL4 protein bound
to a rabbit anti-GAL4 antibody coated on the surface ofFigure 5 Binding activity of TfRscFv-GAL4 fusion protein to normal ti
blood vessel (E) and stomach (F) were dissected to 5μm to creat the tissue
single-chain antibody was used for the detection of TfR expression, using p
each tissue were indicated in A-F (SP: × 400).a microtiter plate in a dose-dependent manner. Further-
more, the OD495 value increased with the parallel increase
of the protein concentration (0.078~10 μg/ml) as shown in
Figure 6. Thus, the GAL4 portion among TfRscFv-GAL4
fusion protein retained its high avidity for binding to rabbit
anti-GAL4 antibody and it suggested the fusion protein
re-naturation did not impair the GLA4 activity.
Functional characterization of the fusion proteins
The ability of protein-DNA binding was used to assess
the biological activity of GLA4 in TfRscFv-GAL4 fusionssues. Normal tissue heart (A), liver (B), spleen (C), adrenal cortex (D),
slides, 10 individual samples were tested for each tissue. TfRscFv-GAL4
arental mouse anti-TfR antibody as positive control. Typical results of
Figure 6 Detection of GAL4 DNA binding domain in TfRscFv-GAL4 with ELISA. TfRscFv-GAL4 was coated in the 96 well plates at different
concentration, GAL4 protein was used a positive control. The absorption of OD495 nm was used for the detection of yellow products of OPD
reacted by HRP.
Figure 7 Transfection efficiency of various complexes in HepG-
2 cells determined by FCM Analysis. First, 1 × 105 cells in 6-
welled plates were exposed to protein-DNA complex with molar
ratio of 1:2.5 (protein to DNA) with or without fusion protein, and
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tion, the purified protein were then added to the plasmids
with varying concentration to form the protein-DNA
complex which were analyzed by electrophoresis on 4.5%
gradient natural (non-SDS) PAGE followed by Western
analysis, it showed that only one protein band could be
seen but the moved protein band was dose-dependent
with addition of DNA plasmids with the optimal molar
ratio of protein to plasmid was 1:2.5 (data not shown).
These constitutive proteins also served as a basis of com-
parison for the activities of the fusion protein. Flow cyto-
metry was used to analyze the transfection efficiency of
the protein-DNA complex mediated by TfRscFv portion.
After a 48-hour incubation, expression of the GFP re-
porter gene was found in (43.0±1.85)% of HepG-2 cells
that had been transfected with the mammalian expression
plasmid of GAL4rec-GFP-pGes in the complex group
(TfRscFv-GAL4+GAL4rec-GFP-pGes), in (5.2±0.23)% and
(1.7±0.18)% of cells transfected with control and in
(3.9±0.34)% transfected with naked DNA plasmid. It indi-
cated that the endocytosis of the TfRscFv-targeted com-
plex to tumor cells was significantly higher than those
without TfRscFv as target molecule. In addition, Figure 7
in columns B,D,F, and G also illustrated that the capability
of TfRscFv-GAL4 to mediate transfer GAL4rec-GFP-pGes
expression plasmid into HepG2 cells as compared to
GFP-pGes plasmid without GLA4, TfRscFv alone did not
exhibit any DNA-binding capacity, confirming that the
DNA-binding capacity of TfRscFv-GAL4 was strictly a
function of the GAL4 component.then they were further incubated for 48 h. For flow cytometry,
HepG-2 cells after transfection with pCMV-GFP were washed,
trypsinized and quantified using the FACS machine as described in
Materials and Methods. Data are expressed as relative percentage of
GFP-expression cells/total cells(mean±standard deviation, obtained
from triplicate wells). Columns represented the transfection
efficiency in different complex groups: (5.2±0.23)% for Column A,
(1.7±0.18)% for Column B, (43.0±1.85)% for Column C, (2.9±0.23)%
for Column D, (3.8±0.32)% for Column E, (2.5±0.15)% for Column F,
(3.9±0.34)% for Column G, (3.1±0.26)% for Column H, The
experiments were repeated 3 times with similar results. Column C
showed 8~10 folds higher than other columns in transfection
efficiency (*p<0.01).Discussion
Recently, non-viral vectors are under intense investiga-
tion as a safer alternative for gene therapy. For success-
ful delivery, efficient and specific targeting of an active
agent to the desired site is a critical factor for overco-
ming many barriers to carry DNA to nuclear localization
and transcription [19]. Some of the most common
non-viral vectors include polyethylenimine, dendrimers,
chitosan, polylysine, and many types of peptides, which
are generally cationic in nature and able to interact withplasmid DNA through electrostatic interactions [20].
Peptide-based vectors are advantageous over other non-
viral strategies in that attachment of a peptide ligand to
the polyplex will allow targeting to specific receptors and/
or specific cell types, particularly in cancer cells [21].
However, an important drawback of the chemical coupling
procedure is the difficulty in producing a reproducible
and homogeneous product. Genetic engineering provides
an alternative approach for large scale production of
homogeneous Ab-GLA4 fusion proteins.
Previous studies have consistently suggested that TfR
is expressed more abundantly in malignant tissues than
that in their healthy counterparts [3-8]. Similarly, serum
levels for soluble transferrin receptor (sTfR) in patients
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nificantly increased as compared with those of normal
controls [22]. Administration of anti-TfR antibody sup-
pressed tumor cells growth in vitro [23]. Most import-
antly, TfR served as an endocytotic receptor which could
carry the vector for uptake by the tumor cells [24].
Based on these findings, anti-TfR antibody is now
considered as an alternative for diagnosis by imaging
localization and for treatment targeting tumors [9,25-30].
The TfR-specific monoclonal or chimeric antibodies
(mAbs) have been developed and used as an alterna-
tive therapeutic approach to kill malignant cells both
in vitro and in vivo [31-33]. Although promising, this
approach requires that unique chimeric molecules be
constructed for each specific application or incapabi-
lity to penetrate tissues for the high molecule weight
of complete human-mouse chimeric TfR antibody. Thus,
it also faces a formidable challenge which sometimes can
lead to a decreased activity or loss of activity of one or
both of the covalently conjugated partners. To overcome
these limitations, it is therefore desirable to develop a uni-
versal delivery system that eliminates the need for a spe-
cific construct for each individual application.
The single chain antibody possesses the property to be
integrated with different proteins for preparing some tu-
mor targeting vectors (e.g. the complex constructed by
chemical coupling method or the fusion protein con-
structed by gene engineering technique). Another critical
feature for the single chain antibody is the low molecular
weight (about 27 KDa, the 1/3 of chimeric antibody),
which renders it with enhanced capability to penetrate
tissues and cells. If TfRscFv is inserted into a eukaryo-
cyte expression vector, the vector would be much more
efficiently intaken by malignant cells. TfRscFv can be
expressed in tumor cells by the vector. By using this ap-
proach, the efficiency for cancer therapy has been sig-
nificantly improved and the dosage for anti-tumor drugs
can also be reduced [34,35].
GAL4 is an 881-amino-acid protein with a Zn-Cys
binuclear cluster type DNA-binding domain which is a
positive regulator for galactose-induced gene expression
[36]. The DNA-binding domain can specifically bind to
a 17bp recognizing sequence motif (GAL4rec). Previous
studies demonstrated that the fusion protein GAL4/Inv
could be used in a DNA delivery system to target tumor
cells [2]. Therefore, GAL4 could be used as a carrier for
a plasmid containing the GAL4rec gene sequence.
In the current investigation, we generated and charac-
terized bifunctionally active a TfRscFv-GAL4 fusion de-
rived from plasmid pUC19 and pABgal4. TfRscFv-GAL4
with hexahistidine residues at the N-terminus were
expressed in E. coli and recovered from the inclusion
bodies with subsequent application of metal-chelate
affinity chromatography. The fusion protein describedin the present study is the first example of recombi-
nant TfR single-chain monovalent antibodies with GAL4
DNA-binding activity produced in prokaryotic expres-
sion system, whereas either constituent component of
recombinant protein showed individual activity through
the following assays.
FCM assay revealed that the TfRscFv-GAL4 fusion
protein is capable of binding to tumor cells, whose im-
mune-reactivity is consistent with the parental anti-TfR
monoclonal antibody. Therefore, our studies provided
direct evidence that TfRscFv -GAL4 fusion protein, in-
stead of GAL4 protein, could bind to various tumor
cells. We also found that the binding rate for the
TfRscFv-GAL4 fusion protein with seven different tumor
cell lines varied between 8.23% and 54.11%. The differ-
ences for the binding rate may account for TfR being
found expressed preferentially in the proliferation or dif-
ferentiation stage of these cells rather than G0 stage,
which was consistent with the results from Crepin R
et al. [37] and our own results previously [12]. ELISA
analysis indicated that the TfRscFv-GAL4 fusion protein
can bind to anti-GAL4 antibody. Therefore, it showed
that the fusion protein retained GLA4 activity and could
also be served as a marker to evaluate the binding cap-
ability of TfRscFv with tumor cells. By using a mouse
antibody against GAL4 and a FITC-labeled anti-mouse
antibody, FCM assay was applied to detect the binding
capability of the fusion protein with cells expressing TfR.
Similarly, an HRP-labeled anti-mouse antibody could
be used for detecting the binding capability of the
fusion protein with tissues through TMA assay. Immu-
nohistochemical studies in TMA indicated that both
TfRscFv-GAL4 fusion protein and the mouse anti-TfR
monoclonal antibody could bind to gastric cancer cells
as well as breast cancer cells. In sharp contrast, neither
GAL4 protein nor mouse non-specific IgG showed such
binding activity, indicating that TfRscFv-GAL4 fusion
protein binding to human gastric cancer cells and hu-
man breast cancer cells is through the TfRscFv domain
but not GAL4 protein domain. Furthermore, except for
5 normal liver tissues with weekly binding activity,
TfRscFv-GAL4 fusion protein and the mouse anti-TfR
antibody failed to show any binding activity to normal
tissues, suggesting that TfRscFv-GAL4 fusion protein
was relatively specific to tumor tissues.
We designed the DNA-binding functional assay to
further determine the fusion protein function. After con-
jugating the TfRscFv-GAL4 to the plasmid GAL4rec-
pGes which was engineered to include a specific
long sequence in the upstream activating sequence
(5'-cggrnnrcynyncnccg-3', GAL4rec) and reporter gene
GFP, protein-DNA complex incubated with hepatic car-
cinoma cells HepG2, and the GFP expression in cells was
detected by fluorescence microscopy. Cells treated with
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strong fluorescence signal, but cells treated with GAL4
lacking the TfRscFv, or those treated with TfRscFv without
GLA4 portion, or naked DNA alone almost did not fluo-
resce. These data demonstrated that this process was in
fact GLA4-DNA recognition and then mediated through
the attachment of the scFv to the transferrin receptor on
the tumor cells, and the fusion protein has the unique
capacity to mediate gene transfer. Taken together, this
protein-DNA may be considered as a promising candidate
for developing novel tumor-targeted gene delivery for sys-
temic gene therapy of various human cancers.
Conclusions
We generated a novel DNA delivery vehicle containing
single chain variable fragment of anti-transferrin recep-
tor (TfRscFv) and GLA DNA binding domain (GAL4-
DBD). GAL4-DBD is capable of binding DNA contain-
ing its specific binding sequence, and TfRscFv binding
TfR on tumor cells is able to uptake by tumor cells
through cell membranes to deliver DNA. This approach
entailed covalently conjugating the fusion protein
TfRscFv-GAL4 to the plasmid via a GAL4 at the 3’-end
of the protein recognizing GAL4rec on the transfected
plasmid (GAL4rec-GFP-pGes). Our results showed that
this recombinant protein does not impair the immuno-
logical activity or targeting ability of the TfRscFv, as well
as the functional avidity of GLA4 recognizing the GAL4rec
sequence. The TfRscFv-GAL4 targeted the protein-DNA
complex to tumor cells and enhanced the transfection
efficiencies in vitro, but it did not exhibit the binding
activity for normal tissues. The potential utility and ap-
peal of this peptide-guided gene delivery lies with its in-
ternalization, the ability to control the nature of its
constituent parts, and ease of generation. Briefly, this
investigation provided basis for TfRscFv-GAL4 applica-




All cancer cell lines such as HepG-2 (hepatocellular car-
cinoma cell line), HeLa (human cervical carcinoma cell
line), MCF-7 (human breast cancer cell line), SLC-89
(human lung adenocarcinoma cell line), MDA-MB-231
(breast cancer cell line), HL-60 (Human promyelocytic
leukemia cells) and MKN-28 (gastric cancer cell line)
were purchased from ATCC. They were stored in our la-
boratory and cultured with the basal medium DMEM
(GIBCO, USA) or RPMI 1640 (GIBCO, USA) containing
10% fetal bovine serum (GIBCO, USA) at 37°C with 5%
CO2. For transfection, 1 × 10
5 cells were initially seeded
in 1ml of medium in 12-well culture plates and trans-
fected at 80% confluency.Prokaryotic expression vector of the TfRscFv-GAL4-
pET28a
A fragment for the TfRscFv cDNA was directly amplified
by PCR using the amplimers 5'-CGGCCATGGCC
CACGTTCAGCTGCAGCAGT-3' and 5'-GGCGGAAT
TCTTTGATTTCCAGCTTGGTC-3' from a pUC19 plas-
mid containing the TfRscFv sequence as described before
[12]. The fragment for GAL4 was released from a pABgal4
plasmid (kindly provided by Dr. Bert W. O' Malley, Baylor
College of Medicine, Houston, TX) by digestions of EcoRI
and NotI restriction endonucleases (Thermo Scientific
Fermentas). The amplimers used were: 5'-CCG-GTAT
GGCTAGCCTGCAGAAGCTACTGTCTTCTATCG-3'
and 5'-GAGCCGACCGGTACCTCAACTTACAGTCA
ACTGTC-3'. Both fragments for TfRscFv and GAL4 were
introduced by ligation into expression vector pET28a (+)
at the NcoI and NotI restriction site, respectively. In the
resulting construct, pET28a (+), the hexahistidine se-
quence was fused in-frame to the GAL4 DNA-binding do-
main, followed by the (GGGGS)3 flexible peptide linker
sequence and the carboxy-terminal 228 amino acids of
TfRscFv (Figure 1). The resulted prokaryotic expression
plasmid was referred as TfRscFv-GAL4-pET, which was
subsequently transfected into E.coli BL21 (DE3) strain for
plasmid DNA preparation. The inserted sequences were
confirmed by restriction enzyme digestion with an agarose
gel electrophoresis and DNA sequencing using an ABI
PRISM W 377 DNA Sequencer.
Expression and purification of TfRscFv-GAL4 fusion
protein
E. coli BL21 carrying plasmid TfRscFv-GAL4-pET was
grown at an A600 of 0.5~0.7 overnight. An 0.5 ml aliquot
of inoculate was added to 20 ml Luria-Bertani medium
(LB) containing 25 μg/ml ampicillin and 50 mM glucose
(LBG). The synthesis of recombinant TfRscFv-GAL4 fu-
sion protein was induced with 1.0mM IPTG (isopropyl-β-
D-thiogalacto-pyranoside) (Thermo Scientific Fermentas).
Following 6h of incubation at different temperatures of
23°C, 30°C, 37°C, cells were harvested by centrifugation at
5000 g for 10 min at 4°C. Cell pellets were frozen at −20°C
and resuspended in lysis buffer (6M guanidine-HCl, 20
mM sodium phosphate pH 7.8, 500 mM sodium chloride),
sonicated 3×, and 0.45 μm filtered to remove insoluble
debris. The extract of inclusion bodies was analyzed by
12.5% polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions described as before [2,12]. Be-
cause TfRscFv-GAL4-pET expression vectors introduce a
(His)6 tail at the C-terminus of the recombinant TfRscFv-
GAL4, The solubilized fusion protein was purified by
immobilized metal affinity chromatography (IMAC)
through the binding of His-tag with Ni2+-nitrilotriacetate
(Ni-NTA) agarose column (Invitrogen, USA) according
to the manufacturer’s protocol as previously described
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inclusion bodies were passed through the column, the
column was washed with 10 column volumes of 6M
guanidine, 0.1 M Tris–HCl (pH 7.0) followed by 10 bed
volumes of 6M urea, 50 mM Tris–HCl, 10 mM imidazole
and 20 bed volumes of 6 M urea, 50 mM Tris–HCl, 50
mM imidazole. TfRscFv-GAL4 was eluted with 20 ml
(4 bed volumes) of 6M urea, 50 mM Tris–HCl, 250 mM
imidazole, and was then dialyzed in TEA (0.4 M L-arginine,
0.1 M Tris–HCl, 2 mM EDTA, pH 7.0) overnight. Opti-
mal dilutions were determined empirically to avoid aggre-
gation during refolding. Protein re-naturation was based
on a procedure developed for the GLA4 fusion protein
[39]. After dialysis, 60-75% of the re-natured protein was
recovered in the soluble fraction after centrifugation. The
concentration of fusion protein was calculated by bicinch-
oninic acid-based protein assay (BCA Protein Assay;
Pierce, Rockford, IL), and plasmids pUC19, pABgal4 trans-
formed E. coli BL21 to express protein as controls.Western blot analysis
E. coli BL21 lysates, and extracted inclusion bodies,
which had been dialyzed in TEA before electrophoresis,
or purified TfRscFv-GAL4, were resolved in 12% SDS–
PAGE (Bio-Rad) under reducing conditions for Western
blotting. Immunoblot analysis was carried out with the
mouse mAb to GLA4 epitope (Sigma) as the primary
antibody, peroxidase labeled horse anti-mouse IgG
(Sigma) was used as the secondary antibody for GLA4
and results were visualized with DAB. Western blot with
human TfR was used to determine the binding activity
of purified TfRscFv-GAL4. Human TfR was electrophor-
esed in SDS-PAGE and blotted as described above. The
membrane was sequentially incubated with the TfRscFv-
GAL4 (primary antibody), the GLA4 mAb, biotinylated
horse anti-mouse IgG (secondary antibody).
Flow cytometry
The antigen-binding activity of TfRscFv in TfRscFv-
GAL4 fusion protein was analysed by an indirect Im-
munofluorescence Assay as described before [12,38].
Briefly, 2 × 105 of HepG-2, HeLa, MCF-7, HL-60, MDA-
MB-231, MKN28 and SLC-89 cells were collected at
logarithmic phase. After washed with washing buffer
(cold PBS, 1% BSA, 1mM CaCl2, 1mM MgCl2), the cells
were incubated with TfRscFv-GAL4 for 20 min at 4°C,
then treated with a mouse anti-GAL4 antibody and
stained with FITC goat anti-mouse IgG. The cells were
next analyzed by flow cytometry using the Cell Quest
software package (Becton–Dickinson FACScalibur, USA).
A mouse anti-TfR monoclonal antibody was used as a
positive control, while the GAL4 protein and mouse non-
specific IgG were used for isotype controls.Construction of tissue microarrays (TMA) and
Immunohistochemistry (IHC)
Paraffin-embedded tissue samples based on availability
of resected tissues from 140 patients with gastric cancer
and 112 patients with breast cancer which were obtained
from the archives of Department of Pathology, Medical
School of Jianghan University, Tongji Hospital of HUST
and Department of Pathology, Medical School of Peking
University. Tissue sections originated from autopsy sam-
ples such as from heart, blood vessels, liver, adrenal cor-
tex, spleen and stomach were used as normal controls
(each tissue included 5 cases), which were provided
by the Department of Pathology, Medical School of
Jianghan University and Tongji Hospital of HUST. The
formalin-fixed, paraffin-embedded tissue blocks and the
corresponding histological HE-stained slides were over-
laid for tissue TMA sampling. Representative areas of
tumor tissues were marked on the slides. A tissue array-
ing instrument (Beecher Instruments, Silver Spring, MD,
USA) was used to punch triplicate 0.6-mm-diameter
cylinders of tissue from selected cancer areas of individ-
ual donor tissue block and re-emb into a recipient paraf-
fin block at a predefined position. Subsequently, multiple
sections (5μm thick) were cut from the TMA tissue array.
IHC was employed to measure the Ag-binding rates
for TfRscFv-GAL4 fusion protein with various tumor
TMA sections. The immunohistochemical study of Ag-
binding was performed using a standard streptavidin-
peroxidase method described previously [40]. The en-
dogenous peroxidase activity was blocked with 3% H2O2
for 10 minutes. For antigen retrieval, slides were immersed
in 10 mM citrate buffer (pH 6.0) and boiled for 15 minutes
in a microwave oven. Non-specific binding was blocked by
5% normal goat serum for 10 minutes. The slides were
treated with a mouse anti-GAL4 antibody after incubated
with TfRscFv-GAL4 against TfR expressing on TMA at
4°C overnight in a moist chamber followed by incubating
with HRP labeled goat anti-mouse IgG (Southern Biotech-
nology Associates, USA) for 20 mins at 37°C, and then
with streptavidin-peroxidase conjugate, each for 30 mins
at room temperature. The parental mouse anti-TfR anti-
body (Mouse anti-TfR group) was used as the positive
control, and Mouse IgG group and GAL4 group, was used
as the negative control, respectively. The TMA were finally
stained with 3, 5-diaminobenzidine (DAB) reagents and
incubated with hematoxylin to stain the nuclei, and results
were evaluated under a light microscope. For the evalu-
ation of TMA staining, a semi-quantitative scoring criter-
ion was used, in which both staining intensity and positive
cells percentage were scored. A staining index (with values
from 0 to 12) was obtained as the intensity of TfR stain-
ing (0=negative, 1=weakly positive, 2=positive, 3=strongly
positive) times the proportion of immune-positive tumor
cells (0%=0; <10%=1; 10%≤ to<50%=2; 50%≤to <75%=3;
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value and ≥2 as positive value. All histological evaluations
were carried out in a double-blind manner by two expert
pathologists (DH and YQ).
ELISA-based binding assay
It was employed to an ELISA-based assay to determine
the protein activity of GAL4 domain for the TfRscFv-
GAL4 fusion protein when bound and not bound to its
special anti-GLA4 antibody. Briefly, the GAL4 or
TfRscFv-GAL4 was coated in a 96-well plate (100 μl/
well) at 4°C overnight. After washes with PBS (contain-
ing 0.005% Tween-20), the plate was blocked for 2 h at
37°C, followed by incubation with a rabbit anti-GAL4
antibody (0.1 μg/ml, Invitrogen, USA) for 2 h at 37°C.
Next, HRP labeled goat anti-rabbit IgG (1:5000, 100 μl/
well, Southern Biotechnology Associates, USA) was ap-
plied and incubated for 1h at 37°C. Freshly prepared
substrate solution (100 μl/well) was finally added and
incubated for 15 min at room temperature, and the
results were read by a photometer at 495 nm (TECAN,
USA) after application of stop solution (50 μl/well) for
color development. As a negative control, the conven-
tional TfRscFv was used.
Functional assay of GAL4-DNA binding
The protein-DNA complex was generated prior to GAL4-
DNA binding assay. Mammalian expression vectors
GAL4rec-GFP-pGes (Shanghai BlueGene Biotech Co.,
Ltd. Shanghai, China) encoding the green fluorescent pro-
tein (GFP) with the human cytomegalovirus promoter
(pCMV), was made by ligating the consensus 17-bp se-
quence(5'-cggrnnrcynyncnccg-3') recognizing GAL4, The
resulting plasmids, which contained eight tandem copies
of the target oligonucleotide and its sequence was identi-
fied by our research group previously(unpublished data),
amplified in the DH5 a strain of E. coli, and purified
according to E.Z.N.A.WPlasmid Maxiprep Kit (OMEGA,
USA) and their concentrations were measured by UV
meter (Gene Spec I, Japan).
Dilutions of purified and re-natured TfRscFv-GAL4 in
re-naturation buffer were mixed with Plasmid DNA
(GAL4rec-GFP-pGes plasmid or GFP-pGes plasmid) in a
total volume of 20 μl with varying concentration ratio of
protein-DNA between 0.5 to 10.0. The mixtures were con-
jugated in the reaction system of protein-DNA linking buf-
fer (25 mM HEPES pH 7.6, 50 mM KCL, 5 mM MgCL2,
100 μM ZnCl2, 0.1 mM EDTA, 0.1% Nonidet P40, 10%
glycerol, 200 μg/ml BSA, 50μl/ml poly(dI-dC)) for 15 min
at 25°C. The solution was mixed well for 10 min by gently
inversion several times to produce the complex of
TfRscFv-GAL4 and GAL4rec-GFP-pGes. Then, 4.5% gra-
dient (non-SDS) PAGE followed by Western analysis was
also used to assess the optimal molar ratio of protein toplasmid as 1:2.5. In Accordance with the complex
transfection protocol [1], the hepatic cancer cells
HepG-2 (5x105/well) were seeded in 12-well culture plates
24h before transfection. The culture medium was replaced
with free-FBS RPMI-1640 medium before the sequential
addition of 0.1 ml protein-DNA complexes of TfRscFv-
GAL4 and GAL4rec-GFP-pGes, after incubation for 5h in
5% CO2 at 37°C, 1 ml of medium with 10% FBS was added
and incubated for another 48h. Alternatively, the purified
protein GAL4, TfRscFv, or the vector (GFP-pGes) com-
plex as different controls and phosphate buffered saline
(PBS) as a blank control, respectively. On the day of har-
vest, cells transfected with pCMV-GFP were washed with
PBS and trypsinized. The transfection efficiency was eval-
uated by scoring the percentage of cells expressing GFP
using a FACS Calibur System (Becton-Dickinson). The
experiments were performed in triplicate, and 10,000 cells
were counted in each experiment.
Statistical analysis
All results from each experiment were expressed as mean ±
SEM with number (n) of observations. Sets of data were
compared with an analysis of variance (ANOVA) or a
Student’s t test. Differences were considered statistically sig-
nificant when P < 0.01. Symbols used in figures were (*) for
P > 0.05 and NS for no significant difference. All statistical
tests were performed using GraphPad Prism version 4.0 for
Windows (Graph pad Software).
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